COMMUNIQUÉS West-GlobeNewswire

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
14/01/2026
— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment — — Savolitinib and osimertinib [...]
BriaCell Therapeutics Announces Pricing of $30 million Public Offering
14/01/2026
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that [...]
Aqua free enters the B2C market with “Shower2go”: a portable travel shower for safer showering on the go – helping to reduce exposure to Legionella
13/01/2026
Hamburg, 12.01.2025 – Aqua free , a leading European provider of drinking-water hygiene solutions, is launching Shower2go, a portable travel shower for consumers. Designed for hotels, holiday rentals, campsite washrooms [...]
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
13/01/2026
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the [...]
Dentsply Sirona and Benco Dental Announce Expanded Partnership to Include Dental Technology Solutions
13/01/2026
Benco Dental will offer Dentsply Sirona’s full portfolio of dental technology solutions, in addition to the consumables portfolio. Expanding the decades-long relationship reflects a shared vision to advance connected [...]
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
13/01/2026
Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately $182 million and $594 million, respectively [...]
Voting Rights and Shares Capital of the Company
13/01/2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Jan. 13, 2026 (GLOBE NEWSWIRE [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
13/01/2026
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 13 janv. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
13/01/2026
Fourth quarter 2025 total revenue expected to be approximately $11.3 million, representing growth of approximately 37% compared to the prior-year period. Received record multi-system order in the fourth quarter from an [...]
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
13/01/2026
- Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodulation regimen - - [...]
INVO Fertility to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
13/01/2026
SARASOTA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility [...]
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
13/01/2026
WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting [...]
Metabo Drops 2026: Is It Legit? Ingredients, Safety Facts, and Consumer Analysis
13/01/2026
Consumer searches for supplement legitimacy increased 26% year-over-year as transparency becomes central purchasing criterion — industry analysis examines what drives "Is It Legit?" search behavior and how liquid [...]
Wegovy Pill vs Wegovy Shot: Oral vs Injectable Semaglutide Differences — 2026 FDA Launch Analysis via Ro.co
13/01/2026
Comprehensive comparison of daily oral vs weekly injectable Wegovy following Novo Nordisk's January 2026 FDA approval of the first oral GLP-1 for chronic weight management — Ro.co telehealth access pathway examination [...]
Best Hair Regrowth Formula 2026 (BioGrow RX): Consumer Report Compares Biotin Supplements to Topical Treatments
13/01/2026
2026 Hair Wellness Report: Biotin Complex vs Topical Serums – Format Selection, Label Transparency, and Daily Routine Fit NORTH LARGO, FL, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational [...]
Best Testosterone Replacement Therapy (TRT) 2026: Taurus Meds Consumer Analysis Examines Online TRT Access and At-Home Testosterone Treatment Options
13/01/2026
Consumer Report Details Low Testosterone Treatment Costs, LabCorp and Quest Lab Testing, Licensed Provider Access, and What Men Need to Know Before Starting Online TRT WILMINGTON, DE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- [...]
Wegovy Pill Legitimacy Examined: 2026 Consumer Analysis Investigates Ro's Oral GLP-1 Access Pathway and No-Insurance Cash-Pay Options
13/01/2026
As Novo Nordisk launches first FDA-approved oral weight loss medication, independent examination evaluates Ro's direct-to-patient distribution model, pricing transparency, and telehealth access structure for patients [...]
Best Electrolyte Supplement Analysis 2026: Seaonic Challenges Top Hydration Packets With Ocean-Sourced Minerals
13/01/2026
A deep-dive into what's driving the shift toward seawater-derived electrolytes—and how Seaonic's published disclosures compare with common verification criteria DENVER, CO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disclaimer: [...]
Option Care Health Announces Preliminary Fourth Quarter & Full Year 2025 Financial Results and Preliminary Financial Guidance for Full Year 2026
12/01/2026
BANNOCKBURN, Ill., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum